VJHemOnc is committed to improving our service to you

ASCO 2018 | Results of the COG AALL0434 trial for T-cell malignancies

VJHemOnc is committed to improving our service to you

Kimberly Dunsmore

Patients with T-cell leukemias typically have a worse prognosis than those with B-cell malignancies. In this interview, Kimberly Dunsmore, MD, from Virginia Tech Carilion School of Medicine, Roanoke, VA, discusses the results of the COG AALL0434 trial (NCT00408005), which is the largest T-cell malignancy trial to date. The aims of this trial were to investigate whether it is safe to administer nelarabine to patients with T-cell lymphoblastic lymphoma and T-cell acute lymphoblastic leukemia, and whether treating these patients with high-dose or escalating-dose methotrexate is more effective when they are given as part of complex chemotherapy protocols. Prof. Dunsmore lastly speaks to the next steps for this study. This video was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter